

Molecular Infectious Disease Testing Market Outlook 2026-2034: Market Share, and Growth Analysis By Products and Services (Reagents & Kits, Instruments, Services & Software), By Type (Multiplex Testing, Singleplex Testing), By Test Type, By Disease, By Technology, By End-User

<https://marketpublishers.com/r/M329EC36A55BEN.html>

Date: November 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: M329EC36A55BEN

Abstracts

The Molecular Infectious Disease Testing Market is valued at USD 9.58 billion in 2025 and is projected to grow at a CAGR of 14.3% to reach USD 31.9 billion by 2034.

Molecular Infectious Disease Testing Market

The Molecular Infectious Disease Testing Market spans assay chemistries (RT-PCR, isothermal NAATs, CRISPR, sequencing), consolidated analyzers and sample-to-answer cartridges, open reagent kits, syndromic panels (respiratory, GI, STI, sepsis), high-throughput lab automation, and near-patient/POC platforms deployed across hospital labs, reference networks, public health, physician offices, pharmacies, and at-home collection models. Growth is powered by the need for rapid, accurate organism detection and resistance markers that guide targeted therapy, antimicrobial stewardship, and outbreak control. Post-pandemic, demand is normalizing from peak respiratory volumes toward balanced menus - multi-pathogen respiratory, strep/flu/COVID combos, STI and vaginitis panels, bloodstream infection ID/AST workflows, and TB/HPV/viral load programs. Differentiation centers on turnaround time and ease-of-use (true sample-to-answer), breadth/depth of menus, per-test economics under shifting reimbursement, data connectivity (LIS/LIMS, public health reporting), and supply resilience. Reference labs emphasize total cost-per-reportable and uptime across seasonal surges; health systems value integrated stewardship rules and reflex

pathways to culture or phenotypic AST. Innovation focuses on multiplexing without over-testing penalties, resistance gene detection (ESBL, carbapenemase, macrolide), extraction-free workflows, lyophilized reagents for cold-chain lightness, and decentralized testing with cloud fleet management. Challenges include right-sizing panels to clinical indications, navigating utilization management, harmonizing results across platforms, and maintaining quality in decentralized sites. Overall, the market is shifting from pandemic boom to durable, evidence-anchored growth where assay menus, operational reliability, and informatics deliver faster, appropriate therapy with defensible economics.

Molecular Infectious Disease Testing Market Key Insights

Menu strategy beats single tests: Vendors winning share pair high-value syndromic panels with targeted assays (e.g., strep A, CT/NG, *C. difficile*) to fit utilization rules, enabling clinicians to start narrow and reflex broader when warranted - protecting reimbursement while preserving clinical yield.

Sample-to-answer is table stakes; uptime is the moat: True walk-away workflows, minimal hands-on time, and integrated extraction are expected; the differentiators are instrument reliability, hot-swap modules, and remote diagnostics that sustain throughput during seasonal spikes.

Right-sized multiplexing cuts waste: Adaptive or hierarchical panel logic (mini-panels, “add-on” reflexes) reduces unnecessary positives and cost, while still covering co-infections and atypical pathogens when pre-test probability is high.

Resistance markers move earlier in the pathway: Rapid carbapenemase/ESBL genes on positive blood cultures, macrolide resistance for *M. genitalium*, and rifampin/INH markers for TB accelerate effective therapy and infection control beyond organism ID alone.

Decentralization demands guardrails: CLIA-waived/near-patient systems expand access in EDs, urgent care, and pharmacies, but succeed only with e-learning, QA dashboards, onboard controls, and auto-reporting that minimize operator variability.

From results to decisions via informatics: LIS/LIMS integration, antibiogram-aware decision support, and public health e-reporting turn molecular outputs into actionable steps; analytics spot clusters and guide stewardship programs in real

time.

Cost-per-result over list price: Health systems model tech time, repeat rates, QC burden, and service SLAs; reagent-rental and volume-tier pricing remain common, with contracting that protects supply during surges.

Supply chain resilience is a bid winner: Dual-sourced plastics, lyophilized mixes, and regional kitting plants reduce stockouts; transparent change-control and lot-to-lot bridging protocols shorten revalidation cycles.

Sequencing complements - not replaces - NAATs: Rapid targeted panels manage front-line care; WGS/amplicon sequencing supports outbreak tracing, variant surveillance, and rare pathogen ID within reference labs and public health.

Quality and compliance are non-negotiable: External proficiency, onboard process controls, contamination safeguards, and traceable e-logs keep decentralized fleets inspection-ready and protect diagnostic credibility.

Molecular Infectious Disease Testing Market Regional Analysis

North America

Hospital and reference labs rebalance menus from pandemic peaks to steady respiratory combos, STI, and sepsis workflows. Procurement emphasizes total cost-per-reportable, analyzer uptime, and LIS/public health connectivity. Decentralized testing grows in urgent care and pharmacy settings under strict quality programs; stewardship-linked reflex rules and rapid resistance markers influence formulary decisions.

Europe

Guideline-driven adoption favors CE-marked multiplex panels with clear clinical indications and cost-effectiveness dossiers. National surveillance integration and data privacy shape informatics. Public tenders stress lifecycle economics, supply security, and sustainability (packaging, energy use). TB/HPV programs and rapid BSI ID with resistance markers sustain volumes across public hospital networks.

Asia-Pacific

Rapid capacity build-out in urban centers and rising private labs drive placements from compact POC instruments to high-throughput automation. Menu focus spans respiratory, GI, TB, HPV, and dengue/region-specific panels. Local manufacturing and distributor service depth are decisive; cloud fleet management and e-training support scale across diverse sites and languages.

Middle East & Africa

Flagship hospitals and national programs expand molecular capacity for TB, viral hepatitis, and maternal/child health, with targeted respiratory/STI panels in private care. Heat-resilient logistics, lyophilized reagents, and robust remote support are critical. Central labs serve spokes via hub-and-spoke models; quality frameworks and connectivity underpin sustainable decentralization.

South & Central America

Public–private collaborations expand access in urban hubs; priorities include syndromic respiratory, GI, and STI testing with reagent-rental economics. Labs value instruments that tolerate power/connectivity variability and offer strong remote diagnostics. Training, proficiency testing, and clear utilization pathways help manage costs while improving time-to-appropriate therapy across mixed healthcare systems.

Molecular Infectious Disease Testing Market Segmentation

By Products and Services

Reagents & Kits

Instruments

Services & Software

By Type

Multiplex Testing

Singleplex Testing

By Test Type

Laboratory Tests

Point Of Care Tests

By Disease

Respiratory Infectious Diseases

Gastrointestinal Infectious Diseases

Sexually Transmitted Diseases

Hospital-Acquired Infections

Vaginitis

Meningitis

Vector-Borne Diseases

Others

By Technology

Polymerase Chain Reaction

Isothermal Nucleic Acid Amplification Technology

DNA Sequencing & Next-Generation Sequencing

In Situ Hybridization

DNA Microarrays

Others

By End-User

Diagnostic Laboratories

Hospitals & Clinics

Others

Key Market players

Roche Diagnostics, Abbott Molecular, Hologic, Thermo Fisher Scientific, bioMérieux (BioFire), Cepheid (Danaher), QIAGEN, BD (Becton, Dickinson and Company), DiaSorin (Luminex), Seegene Inc., BGI Genomics, QuidelOrtho, Meridian Bioscience, Oxford Nanopore Technologies, Bio-Rad Laboratories

Molecular Infectious Disease Testing Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping, and scenario-based modelling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends. Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behaviour are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Molecular Infectious Disease Testing Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and

innovative startups contributing to market disruption. Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Molecular Infectious Disease Testing market data and outlook to 2034

United States

Canada

Mexico

Europe — Molecular Infectious Disease Testing market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Molecular Infectious Disease Testing market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Molecular Infectious Disease Testing market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Molecular Infectious Disease Testing market data and outlook to 2034

Brazil

Argentina

Chile

Peru

* We can include data and analysis of additional countries on demand.

Research Methodology

This study combines primary inputs from industry experts across the Molecular Infectious Disease Testing value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Molecular Infectious Disease Testing industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Molecular Infectious Disease Testing Market Report

Global Molecular Infectious Disease Testing market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Molecular

Infectious Disease Testing trade, costs, and supply chains

Molecular Infectious Disease Testing market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Molecular Infectious Disease Testing market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Molecular Infectious Disease Testing market trends, drivers, restraints, and opportunities

Porter's Five Forces analysis, technological developments, and Molecular Infectious Disease Testing supply chain analysis

Molecular Infectious Disease Testing trade analysis, Molecular Infectious Disease Testing market price analysis, and Molecular Infectious Disease Testing supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Molecular Infectious Disease Testing market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

* The updated report will be delivered within 3 working days

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET SUMMARY, 2025

- 2.1 Molecular Infectious Disease Testing Industry Overview
 - 2.1.1 Global Molecular Infectious Disease Testing Market Revenues (In US\$ billion)
- 2.2 Molecular Infectious Disease Testing Market Scope
- 2.3 Research Methodology

3. MOLECULAR INFECTIOUS DISEASE TESTING MARKET INSIGHTS, 2024-2034

- 3.1 Molecular Infectious Disease Testing Market Drivers
- 3.2 Molecular Infectious Disease Testing Market Restraints
- 3.3 Molecular Infectious Disease Testing Market Opportunities
- 3.4 Molecular Infectious Disease Testing Market Challenges
- 3.5 Tariff Impact on Global Molecular Infectious Disease Testing Supply Chain Patterns

4. MOLECULAR INFECTIOUS DISEASE TESTING MARKET ANALYTICS

- 4.1 Molecular Infectious Disease Testing Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Molecular Infectious Disease Testing Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Molecular Infectious Disease Testing Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Molecular Infectious Disease Testing Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Molecular Infectious Disease Testing Market
 - 4.5.1 Molecular Infectious Disease Testing Industry Attractiveness Index, 2025
 - 4.5.2 Molecular Infectious Disease Testing Supplier Intelligence
 - 4.5.3 Molecular Infectious Disease Testing Buyer Intelligence
 - 4.5.4 Molecular Infectious Disease Testing Competition Intelligence
 - 4.5.5 Molecular Infectious Disease Testing Product Alternatives and Substitutes

Intelligence

4.5.6 Molecular Infectious Disease Testing Market Entry Intelligence

5. GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET STATISTICS – INDUSTRY REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

5.1 World Molecular Infectious Disease Testing Market Size, Potential and Growth Outlook, 2024- 2034 (\$ billion)

5.1 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By Products and Services, 2024- 2034 (\$ billion)

5.2 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By Type, 2024- 2034 (\$ billion)

5.3 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By Test Type, 2024- 2034 (\$ billion)

5.4 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By Disease, 2024- 2034 (\$ billion)

5.5 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By Technology, 2024- 2034 (\$ billion)

5.6 Global Molecular Infectious Disease Testing Sales Outlook and CAGR Growth By End-User, 2024- 2034 (\$ billion)

5.7 Global Molecular Infectious Disease Testing Market Sales Outlook and Growth by Region, 2024- 2034 (\$ billion)

6. ASIA PACIFIC MOLECULAR INFECTIOUS DISEASE TESTING INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

6.1 Asia Pacific Molecular Infectious Disease Testing Market Insights, 2025

6.2 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By Products and Services, 2024- 2034 (USD billion)

6.3 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By Type, 2024- 2034 (USD billion)

6.4 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By Test Type, 2024- 2034 (USD billion)

6.5 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By Disease, 2024- 2034 (USD billion)

6.6 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By Technology, 2024- 2034 (USD billion)

6.7 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast By End-

User, 2024- 2034 (USD billion)

6.8 Asia Pacific Molecular Infectious Disease Testing Market Revenue Forecast by Country, 2024- 2034 (USD billion)

6.8.1 China Molecular Infectious Disease Testing Market Size, Opportunities, Growth 2024- 2034

6.8.2 India Molecular Infectious Disease Testing Market Size, Opportunities, Growth 2024- 2034

6.8.3 Japan Molecular Infectious Disease Testing Market Size, Opportunities, Growth 2024- 2034

6.8.4 Australia Molecular Infectious Disease Testing Market Size, Opportunities, Growth 2024- 2034

7. EUROPE MOLECULAR INFECTIOUS DISEASE TESTING MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

7.1 Europe Molecular Infectious Disease Testing Market Key Findings, 2025

7.2 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By Products and Services, 2024- 2034 (USD billion)

7.3 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By Type, 2024- 2034 (USD billion)

7.4 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By Test Type, 2024- 2034 (USD billion)

7.5 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By Disease, 2024- 2034 (USD billion)

7.6 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By Technology, 2024- 2034 (USD billion)

7.7 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown By End-User, 2024- 2034 (USD billion)

7.8 Europe Molecular Infectious Disease Testing Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)

7.8.1 Germany Molecular Infectious Disease Testing Market Size, Trends, Growth Outlook to 2034

7.8.2 United Kingdom Molecular Infectious Disease Testing Market Size, Trends, Growth Outlook to 2034

7.8.2 France Molecular Infectious Disease Testing Market Size, Trends, Growth Outlook to 2034

7.8.2 Italy Molecular Infectious Disease Testing Market Size, Trends, Growth Outlook to 2034

7.8.2 Spain Molecular Infectious Disease Testing Market Size, Trends, Growth Outlook

to 2034

8. NORTH AMERICA MOLECULAR INFECTIOUS DISEASE TESTING MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

8.1 North America Snapshot, 2025

8.2 North America Molecular Infectious Disease Testing Market Analysis and Outlook By Products and Services, 2024- 2034 (\$ billion)

8.3 North America Molecular Infectious Disease Testing Market Analysis and Outlook By Type, 2024- 2034 (\$ billion)

8.4 North America Molecular Infectious Disease Testing Market Analysis and Outlook By Test Type, 2024- 2034 (\$ billion)

8.5 North America Molecular Infectious Disease Testing Market Analysis and Outlook By Disease, 2024- 2034 (\$ billion)

8.6 North America Molecular Infectious Disease Testing Market Analysis and Outlook By Technology, 2024- 2034 (\$ billion)

8.7 North America Molecular Infectious Disease Testing Market Analysis and Outlook By End-User, 2024- 2034 (\$ billion)

8.8 North America Molecular Infectious Disease Testing Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)

8.8.1 United States Molecular Infectious Disease Testing Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.8.1 Canada Molecular Infectious Disease Testing Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.8.1 Mexico Molecular Infectious Disease Testing Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA MOLECULAR INFECTIOUS DISEASE TESTING MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

9.1 Latin America Molecular Infectious Disease Testing Market Data, 2025

9.2 Latin America Molecular Infectious Disease Testing Market Future By Products and Services, 2024- 2034 (\$ billion)

9.3 Latin America Molecular Infectious Disease Testing Market Future By Type, 2024- 2034 (\$ billion)

9.4 Latin America Molecular Infectious Disease Testing Market Future By Test Type, 2024- 2034 (\$ billion)

9.5 Latin America Molecular Infectious Disease Testing Market Future By Disease, 2024- 2034 (\$ billion)

9.6 Latin America Molecular Infectious Disease Testing Market Future By Technology, 2024- 2034 (\$ billion)

9.7 Latin America Molecular Infectious Disease Testing Market Future By End-User, 2024- 2034 (\$ billion)

9.8 Latin America Molecular Infectious Disease Testing Market Future by Country, 2024- 2034 (\$ billion)

9.8.1 Brazil Molecular Infectious Disease Testing Market Size, Share and Opportunities to 2034

9.8.2 Argentina Molecular Infectious Disease Testing Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA MOLECULAR INFECTIOUS DISEASE TESTING MARKET OUTLOOK AND GROWTH PROSPECTS

10.1 Middle East Africa Overview, 2025

10.2 Middle East Africa Molecular Infectious Disease Testing Market Statistics By Products and Services, 2024- 2034 (USD billion)

10.3 Middle East Africa Molecular Infectious Disease Testing Market Statistics By Type, 2024- 2034 (USD billion)

10.4 Middle East Africa Molecular Infectious Disease Testing Market Statistics By Test Type, 2024- 2034 (USD billion)

10.5 Middle East Africa Molecular Infectious Disease Testing Market Statistics By Disease, 2024- 2034 (USD billion)

10.6 Middle East Africa Molecular Infectious Disease Testing Market Statistics By Technology, 2024- 2034 (USD billion)

10.7 Middle East Africa Molecular Infectious Disease Testing Market Statistics By End-User, 2024- 2034 (USD billion)

10.8 Middle East Africa Molecular Infectious Disease Testing Market Statistics by Country, 2024- 2034 (USD billion)

10.8.1 Middle East Molecular Infectious Disease Testing Market Value, Trends, Growth Forecasts to 2034

10.8.2 Africa Molecular Infectious Disease Testing Market Value, Trends, Growth Forecasts to 2034

11. MOLECULAR INFECTIOUS DISEASE TESTING MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

11.1 Key Companies in Molecular Infectious Disease Testing Industry

11.2 Molecular Infectious Disease Testing Business Overview

11.3 Molecular Infectious Disease Testing Product Portfolio Analysis

11.4 Financial Analysis

11.5 SWOT Analysis

12 APPENDIX

12.1 Global Molecular Infectious Disease Testing Market Volume (Tons)

12.1 Global Molecular Infectious Disease Testing Trade and Price Analysis

12.2 Molecular Infectious Disease Testing Parent Market and Other Relevant Analysis

12.3 Publisher Expertise

12.2 Molecular Infectious Disease Testing Industry Report Sources and
MethodologyOGAMV25R0825

I would like to order

Product name: Molecular Infectious Disease Testing Market Outlook 2026-2034: Market Share, and Growth Analysis By Products and Services (Reagents & Kits, Instruments, Services & Software), By Type (Multiplex Testing, Singleplex Testing), By Test Type, By Disease, By Technology, By End-User

Product link: <https://marketpublishers.com/r/M329EC36A55BEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M329EC36A55BEN.html>